Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in their interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The only material change disclosed is the increase in shareholdings for five specific individuals on November 4, 2010. These changes resulted from the reinvestment of dividends on shares held within Individual Savings Accounts (ISAs) at a price of £12.16 per ordinary share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: November 4, 2010.
- Transaction Type: Purchase of ordinary shares via dividend reinvestment.
- Share Price: £12.16 per ordinary share.
- Directors Involved: Mr A P Witty (15 shares), Mr J S Heslop (8 shares), Mr S M Bicknell (58 shares), Mr E J Gray (7 shares), and Mr D S Redfern (7 shares).
- Notification Date: November 8, 2010.